Professional Documents
Culture Documents
Definies
Leso cerebral por interrupo abrupta do fluxo sanguneo Isqumico ou hemorrgico Arterial ou venoso AVC x AVE x Stroke
Definio da OMS
Um dficit neurolgico: De instalao sbita Com disfuno focal e no global No qual, aps investigao adequada, os sintomas so considerados como de origem vascular no-traumtica Que duram por >24 horas
Epidemiologia
Annually, 15 million people worldwide suffer a stroke. Of these, 5 million die and another 5 million are left permanently disabled, placing immense burdens on family and community. In 2005, it accounted for approximately 10% of all deaths worldwide. Globally, stroke is the second leading cause of death [3].
Epidemiologia
AVCI corresponde a 87% dos avcs nos EUA. ICH and SAH account for approximately 10% and 3% of all strokes, respectively. About 36% to 69% of ICH is deep in location, 15% to 32% is lobar, 7% to 11% is cerebellar, and 4% to 9% is in the brain stem [11].
Epidemiologia - mortalidade
The overall mortality for stroke in the United States in 2004 was 50 per 100,000. About 70% to 80% of all stroke deaths are ischemic. Hemorrhagic strokes are less prevalent but more likely to be fatal. Globally, the average 30-day case fatality following first ischemic stroke is about 22.9% with the exception of Japan (17%) and Italy (33%) According to the Rochester Epidemiologic Project, the risk for death after first ischemic stroke was 7% at 7 days, 14% at 30 days, 27% at 1 year, and 53% at 5 years
FATORES DE RISCO
Hipertenso arterial (7x) Doenas cardacas (isqumicas) (2x) Fibrilao atrial (5x) + valv. (17x) Diabetes (2x) snd. Metablica. Tabaco (1,5x AVC e 1,9x AVCI) Hiperlipidemia (esp. em jovens) Fatores hematolgicos (fibrinognio e homocistena) Apnia obstrutiva do sono Doena carotdea
Score
Duration
Diabetes
Maximal score is 7.
Rothwell et al,
Lancet. 2007;369:283-92
AITs com escore de 5 ou maior devem ser admitidos para investiao e tratamento imediatos.
The CHADS2 criterion offers a risk stratification scheme for individual stroke risk factors in patients who have atrial fibrillation. The CHADS2 acronym stands for congestive heart failure, hypertension, age older than 75 years, diabetes mellitus, and prior stroke or TIA. Individuals receive 1 point for each risk factor except prior stroke or TIA, which receives 2 points The stroke rate increases by 1.5 with each 1-point increase on the CHADS2 score. Subsequent studies have validated this risk scheme and the studys ability to correctly identify those at high or low risk
Fisiopatologia
ISQUEMIA CEREBRAL
AVC HEMORRGICO
Hemorragia Subaracnide
Circulao Cerebral
Circulao Cerebral
LACS
Sind Motora Pura Sind. Sensitiva Pura Disartria Clumsy Hand Hemiparesia Atxica Dficits proporcionados
TACS
Hemiplegia Hemianopsia Disfuno cortical superior (linguagem, funo visuoespacial, nvel de conscincia)
PACS
Dficti S/M + hemianopsia Dficit S/M + disfuno cortical Disfx cortical + hemianopsia Disfx cortical + motor puro (monoparesia) Disfx cortical isolada
POCS
Paralisia de par craniano (nica ou mltipla) ipsilateral + dficit S/M contralateral Dficit S/M bilateral Alterao dos movimentos conjugados dos olhos Disfuno cerebelar sem dficit de trato longo ipsilateral Hemianopsia isolada ou cegueira cortical.
Time is Brain
Um pedao de crebro do tamanho de uma ervilha morre para cada 12 minutos de atraso no tratamento Cada minuto que se espera, voc perde cerca de 2 milhes de clulas cerebrais
26
Arm Drift (patient closes eyes and holds both arms straight out for 10 seconds):
Normalboth arms move the same or both arms do not move at all (other findings, such as pronator drift, may be helpful) Abnormalone arm does not move or one arm drifts down compared with the other
Abnormal Speech (have the patient say you cant teach an old dog new tricks):
Normalpatient uses correct words with no slurring Abnormalpatient slurs words, uses the wrong words, or is unable to speak
1b. NC Questes
1c. NC Comandos
3. Campo Visual
4. Paralisia facial
9. Linguagem
Total:
Inclusion Criteria (all Yes boxes in this section must be checked): Yes Age 18 years or older? Clinical diagnosis of ischemic stroke with a measurable neurologic deficit?
Time of symptom onset (when patient was last seen normal) well established as 180 minutes (3 hours) before treatment would begin?
Contraindications:
Evidence of intracranial hemorrhage on pretreatment noncontrast head CT? Clinical presentation suggestive of subarachnoid hemorrhage even with normal CT? CT shows multi-lobar infarction (hypodensity greater than one third cerebral hemisphere)? History of intracranial hemorrhage? Uncontrolled hypertension: At the time treatment should begin, systolic pressure remains 185 mm Hg or diastolic pressure remains 110 mm Hg despite repeated measurements? Known arteriovenous malformation, neoplasm, or aneurysm? Witnessed seizure at stroke onset? Active internal bleeding or acute trauma (fracture)? Acute bleeding diathesis, including but not limited to Platelet count 100 000/mm3? Heparin received within 48 hours, resulting in an activated partial thromboplastin time (aPTT) that is greater than upper limit of normal for laboratory? Current use of anticoagulant (eg, warfarin sodium) that has produced an elevated international normalized ratio (INR) 1.7 or prothrombin time (PT) 15 seconds?* Within 3 months of intracranial or intraspinal surgery, serious head trauma, or previous stroke? Arterial puncture at a noncompressible site within past 7 days?
Relative Contraindications/Precautions:
Recent experience suggests that under some circumstanceswith careful consideration and weighing of risk-to-benefit ratiopatients may receive fibrinolytic therapy despite one or more relative contraindications. Consider the pros and cons of tPA administration carefully if any of these relative contraindications is present:
Only minor or rapidly improving stroke symptoms (clearing spontaneously) Within 14 days of major surgery or serious trauma Recent gastrointestinal or urinary tract hemorrhage (within previous 21 days) Recent acute myocardial infarction (within previous 3 months) Postmyocardial infarction pericarditis Abnormal blood glucose level (50 or 400 mg/dL 2.8 or 22.2 mmol/L)
*In patients without recent use of oral anticoagulants or heparin, treatment with tPA can be initiated before availability of coagulation study results but should be discontinued if the INR is 1.7 or the partial thromboplastin time is elevated by local laboratory standards.
TOMOGRAFIA COMPUTADORIZADA
CT x RNM
Tissue Status
Perfusion Status
Vessel Status
Bioenergetic Compromise
UCLA Stroke Center
Hemodynamic Compromise
Occlusions or Stenoses
Evoluo radiolgica